IVVD
What one share of Invivyd holds
Biological Products, (No Diagnostic Substances)
Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of monoclonal antibody (“mAb”) therapies for the prevention and treatment of serious viral infectious diseases. We are devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19.
Invivyd’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.22 |
|---|---|
| Profit | −$0.40 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.41 |
| Cash and investments | $0.54 |
| Book value | $0.61 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$5.32 | $0.00 | −$4.34 | — | — |
| 2022 | — | −$2.23 | $0.02 | −$2.05 | — | $3.26 |
| 2023 | $0.00 | −$1.81 | $0.01 | −$1.59 | — | $1.61 |
| 2024 | $0.21 | −$1.43 | $0.00 | −$1.44 | — | $0.56 |
| 2025 | $0.31 | −$0.30 | $0.00 | −$0.34 | — | $0.86 |